In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024

IF 3.7 3区医学 Q2 INFECTIOUS DISEASES

Journal of global antimicrobial resistance Pub Date : 2026-09-01 Epub Date: 2026-08-17 DOI:10.1016/j.jgar.2026.08.011

Boudewijn L.M. DeJonge, Christopher Longshaw, Frank Kung, Sean T. Nguyen, Rodrigo E. Mendes, Yoshinori Yamano

{"title":"In vitro activity of cefiderocol against highly resistant Gram-negative pathogens collected in the SENTRY Surveillance Program between 2020 and 2024","authors":"Boudewijn L.M. DeJonge, Christopher Longshaw, Frank Kung, Sean T. Nguyen, Rodrigo E. Mendes, Yoshinori Yamano","doi":"10.1016/j.jgar.2026.08.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated the in vitro activity of cefiderocol and comparator antibiotics against Gram-negative bacterial isolates with highly resistant phenotypes collected in the SENTRY Antimicrobial Surveillance Program.</div></div><div><h3>Methods</h3><div>Between 2020 and 2024, consecutive Gram-negative bacterial isolates were collected from hospitalized patients in the USA and Europe, Turkey and Israel. Minimum inhibitory concentrations (MICs) were determined by broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Susceptibility was interpreted, as applicable, by CLSI M100 (2026), European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2026), and US Food and Drug Administration (FDA 2026) criteria.</div></div><div><h3>Results</h3><div>Cefiderocol was the only antibiotic that inhibited >90% of carbapenem-non-susceptible isolates by CLSI breakpoints (95.5% of 1229 Enterobacterales, 98.8% of 2807 <em>Pseudomonas aeruginosa</em>, 93.7% of 2254 <em>Acinetobacter baumannii-calcoaceticus</em> species complex, and 99.3% of 2341 <em>Stenotrophomonas maltophilia</em>), and susceptibilities to cefiderocol were >90% across various infection sites. Against multidrug-resistant (MDR) Enterobacterales (N = 10 606) and <em>P. aeruginosa</em> (N = 1817), cefiderocol susceptibility rates were 99.1% and 98.1%, respectively. Susceptibilities to comparator antibiotics ranged between 73.2% (ceftolozane-tazobactam) and 99.8% (aztreonam-avibactam) for MDR Enterobacterales, and between 18.3% (meropenem) and 77.5% (imipenem-relebactam) for MDR <em>P. aeruginosa</em>. 97.4% of 459 difficult-to-treat resistant <em>P. aeruginosa</em> were susceptible to cefiderocol. Additionally, cefiderocol displayed low MIC<sub>50/90</sub> values against <em>Burkholderia cepacia</em> species complex and <em>Achromobacter</em> spp. (0.06/0.5 mg/L and 0.03/0.25 mg/L, respectively).</div></div><div><h3>Conclusions</h3><div>Cefiderocol showed potent in vitro activity against contemporary isolates of Gram-negative bacteria displaying challenging resistance phenotypes.</div></div>","PeriodicalId":15936,"journal":{"name":"Journal of global antimicrobial resistance","volume":"50 ","pages":"Pages 462-469"},"PeriodicalIF":3.7000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of global antimicrobial resistance","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213716526001451","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This study investigated the in vitro activity of cefiderocol and comparator antibiotics against Gram-negative bacterial isolates with highly resistant phenotypes collected in the SENTRY Antimicrobial Surveillance Program.

Methods

Between 2020 and 2024, consecutive Gram-negative bacterial isolates were collected from hospitalized patients in the USA and Europe, Turkey and Israel. Minimum inhibitory concentrations (MICs) were determined by broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Susceptibility was interpreted, as applicable, by CLSI M100 (2026), European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2026), and US Food and Drug Administration (FDA 2026) criteria.

Results

Cefiderocol was the only antibiotic that inhibited >90% of carbapenem-non-susceptible isolates by CLSI breakpoints (95.5% of 1229 Enterobacterales, 98.8% of 2807 Pseudomonas aeruginosa, 93.7% of 2254 Acinetobacter baumannii-calcoaceticus species complex, and 99.3% of 2341 Stenotrophomonas maltophilia), and susceptibilities to cefiderocol were >90% across various infection sites. Against multidrug-resistant (MDR) Enterobacterales (N = 10 606) and P. aeruginosa (N = 1817), cefiderocol susceptibility rates were 99.1% and 98.1%, respectively. Susceptibilities to comparator antibiotics ranged between 73.2% (ceftolozane-tazobactam) and 99.8% (aztreonam-avibactam) for MDR Enterobacterales, and between 18.3% (meropenem) and 77.5% (imipenem-relebactam) for MDR P. aeruginosa. 97.4% of 459 difficult-to-treat resistant P. aeruginosa were susceptible to cefiderocol. Additionally, cefiderocol displayed low MIC_50/90 values against Burkholderia cepacia species complex and Achromobacter spp. (0.06/0.5 mg/L and 0.03/0.25 mg/L, respectively).

Conclusions

Cefiderocol showed potent in vitro activity against contemporary isolates of Gram-negative bacteria displaying challenging resistance phenotypes.

查看原文本刊更多论文

头孢地罗对2020 - 2024年SENTRY监测项目收集的高耐药革兰氏阴性病原体的体外活性

目的：研究头孢地罗和比较抗生素对SENTRY抗菌药物监测项目中收集的具有高耐药表型的革兰氏阴性菌的体外活性。方法：在2020年至2024年期间，从美国、欧洲、土耳其和以色列的住院患者中连续收集革兰氏阴性菌分离株。最低抑菌浓度（mic）采用肉汤微量稀释法，根据临床和实验室标准协会（CLSI）的指南进行测定。药敏性适用CLSI M100（2026）、欧洲抗微生物药物敏感性试验委员会（EUCAST）（2026）和美国食品药品监督管理局（FDA 2026）标准解释。结果：Cefiderocol是唯一对碳青霉烯非敏感菌株CLSI断点有抑制作用的抗生素（1229种肠杆菌95.5%，2807种铜绿假单胞菌98.8%，2254种鲍曼不动杆菌93.7%，2341种嗜麦窄养单胞菌99.3%），不同感染部位对Cefiderocol的敏感性为>90%。头孢地罗对耐多药肠杆菌（N=10 606）和铜绿假单胞菌（N=1817）的敏感性分别为99.1%和98.1%。耐多药肠杆菌对比较抗生素的敏感性在73.2%（头孢唑烷-他唑巴坦）和99.8%（氮曲南-阿维巴坦）之间，耐多药铜绿假单胞菌对比较抗生素的敏感性在18.3%（美罗培南）和77.5%（亚胺培南-乐巴坦）之间。459株DTR铜绿假单胞菌中97.4%对头孢醚敏感。此外，头孢地罗对洋葱伯克霍尔德菌复合体和无色杆菌的MIC50/90值较低（分别为0.06/0.5 mg/L和0.03/0.25 mg/L）。结论：头孢地罗在体外对革兰氏阴性菌具有较强的抗药活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of global antimicrobial resistance INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

8.70

自引率

2.20%

发文量

285

审稿时长

34 weeks

期刊介绍： The Journal of Global Antimicrobial Resistance (JGAR) is a quarterly online journal run by an international Editorial Board that focuses on the global spread of antibiotic-resistant microbes. JGAR is a dedicated journal for all professionals working in research, health care, the environment and animal infection control, aiming to track the resistance threat worldwide and provides a single voice devoted to antimicrobial resistance (AMR). Featuring peer-reviewed and up to date research articles, reviews, short notes and hot topics JGAR covers the key topics related to antibacterial, antiviral, antifungal and antiparasitic resistance.